Eli Lilly and Company $LLY Stock Acquired by China Universal Asset Management Co. Ltd.

Key Points

• China Universal Asset Management increased its Eli Lilly position by 10.1% in the third quarter, bringing its holdings to 9,980 shares worth approximately $11.8 million. Institutional investors collectively own 82.53% of the company.
• Eli Lilly reported strong third-quarter results, with revenue rising 38.6% year over year to $24.4 billion and EPS of $7.48, well above expectations. The company also raised its 2026 revenue forecast to $91 billion–$92 billion, supported by robust Mounjaro and Zepbound demand.
• Analysts remain broadly bullish, but valuation and execution risks persist. The stock trades near its 12-month high at a high earnings multiple, while pricing pressure, one-time benefits in recent results and heavy reliance on GLP-1 drugs could challenge future growth.

China Universal Asset Management Co. Ltd. raised its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 10.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,980 shares of the company's stock after buying an additional 912 shares during the period. China Universal Asset Management Co. Ltd.'s holdings in Eli Lilly and Company were worth $11,823,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. BlackRock Inc. boosted its position in Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock worth $81,009,981,000 after acquiring an additional 1,046,558 shares during the last quarter. State Street Corp increased its stake in shares of Eli Lilly and Company by 1.7% in the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company's stock worth $43,438,262,000 after acquiring an additional 605,752 shares during the last quarter. Bank of America Corp DE purchased a new position in shares of Eli Lilly and Company during the 2nd quarter worth $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Eli Lilly and Company by 1.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company's stock valued at $8,647,153,000 after purchasing an additional 137,364 shares during the period. Finally, Jennison Associates LLC grew its holdings in shares of Eli Lilly and Company by 7.9% in the second quarter. Jennison Associates LLC now owns 5,461,416 shares of the company's stock valued at $6,550,587,000 after purchasing an additional 400,538 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q3 results substantially beat expectations. Revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the $5.68 consensus estimate. Mounjaro sales increased 65% to $10.7 billion and Zepbound sales rose 49% to $5.35 billion. Lilly third-quarter results
• Positive Sentiment: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion previously. Strong demand, broader Medicare access and growing middle-income adoption are supporting expectations for continued GLP-1 expansion. Q3 earnings call highlights
• Positive Sentiment: Analysts raised their price targets and maintained bullish ratings. Scotiabank lifted its target to $1,605 with a “sector outperform” rating, Morgan Stanley raised its target to $1,596 with an “overweight” rating, and RBC moved to $1,600 with an “outperform” rating. Analyst commentary
• Positive Sentiment: Pipeline and portfolio diversification offer additional upside. Positive Phase 3 retatrutide data strengthened Lilly’s competitive position against Novo Nordisk, while oncology, immunology and neuroscience products are beginning to contribute more meaningfully. Lilly growth opportunities
• Negative Sentiment: Investors face execution and valuation risks. Realized prices fell 15%, meaning volume growth must continue to offset pricing pressure. Results also benefited from roughly $900 million in one-time items, and acquired in-process research charges weighed on earnings. With GLP-1 drugs representing a large share of revenue and the stock near its high, expectations are elevated. Reuters earnings report

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the business's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the transaction, the chief accounting officer owned 1,526 shares in the company, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $15,958,170 over the last quarter. Company insiders own 0.14% of the company's stock.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,415.64 on Friday. Eli Lilly and Company has a 12 month low of $834.19 and a 12 month high of $1,449.68. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The firm has a market capitalization of $1.33 trillion, a PE ratio of 45.95, a price-to-earnings-growth ratio of 1.78 and a beta of 0.46. The business's fifty day moving average price is $1,197.72 and its 200 day moving average price is $1,092.57.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping the consensus estimate of $5.71 by $1.77. The firm had revenue of $24.40 billion during the quarter, compared to analysts' expectations of $22.58 billion. Eli Lilly and Company had a return on equity of 93.68% and a net margin of 31.90%. The firm's revenue was up 38.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $7.02 earnings per share. On average, sell-side analysts anticipate that Eli Lilly and Company will post 35.18 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company's dividend payout ratio (DPR) is currently 22.46%.

Analyst Upgrades and Downgrades

LLY has been the topic of several recent analyst reports. Scotiabank boosted their target price on shares of Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the company a "sector outperform" rating in a report on Friday. Cantor Fitzgerald increased their price target on Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the stock an "overweight" rating in a report on Thursday, October 8th. TD Cowen reaffirmed a "buy" rating and set a $1,250.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, September 22nd. HSBC boosted their target price on Eli Lilly and Company from $850.00 to $940.00 and gave the company a "reduce" rating in a research report on Thursday, September 10th. Finally, Royal Bank Of Canada lifted their price objective on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company an "outperform" rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $1,398.43.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.